8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
Mar 27, 2026·SEC
Mereo BioPharma Group plc(MREO)Earnings, Financials & Key Ratios
MREO•NASDAQ
$0.30
Price updated Jun 27, 2026
AboutMereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.Show more
- Revenue$500K
- EBITDA-$37M+19.8%
- Net Income-$42M+3.2%
- EPS (Diluted)-0.26+10.3%
- Gross Margin73.4%
- EBITDA Margin-7421.6%
- Operating Margin-7651.4%
- Net Margin-8375.6%
- ROE-82.21%-6.0%
MREO Price & Volume
Mereo BioPharma Group plc (MREO) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Mereo BioPharma Liquidity
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and clinical execution
"Mereo BioPharma remains a high-risk, pre-revenue biotechnology entity characterized by a reliance on sporadic milestone payments and a significant quarterly R&D expenditure averaging $4.5 million. The company's long-term viability is increasingly constrained by a shrinking asset base, which has declined from $96.1 million in 2024Q2 to $40.6 million as of 2026Q1. Investors should monitor the potential for dilutive financing or strategic out-licensing as the current cash position of $36.2 million faces ongoing pressure from consistent negative free cash flow."
Verdict Logic
the company's reliance on stock-based compensation exceeding $1.5 million per quarter and a rapid depletion of assets from $96.1 million to $40.6 million over two years suggests significant risk to shareholder value.
MREO Growth Metrics
Mereo BioPharma Group plc (MREO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM24.24%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM99.95%
Return on Capital
10 Years-57.31%
5 Years-56.19%
3 Years-68.11%
Last Year-73.46%
MREO Recent Earnings
Mereo BioPharma Group plc (MREO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (30%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.01-150.0%
$0.02
Rev
—
$12M
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.01+0.0%
$0.01
Rev
—
$23M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.01-20.0%
$0.01
Rev
$300,000-94.3%
$5M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.02-100.0%
$0.01
Rev
$685,710
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.01vs $0.02-150.0% | —vs $12M |
| Q2 2026 | Mar 19, 2026 | $0.01vs $0.01+0.0% | —vs $23M |
| Q4 2025 | Nov 10, 2025 | $0.01vs $0.01-20.0% | $300,000vs $5M-94.3% |
| Q3 2025 | Aug 12, 2025 | $0.02vs $0.01-100.0% | $685,710 |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Mereo BioPharma Group plc (MREO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.30 | $47.34M | -1.14 | — | -8375.6% | -82.21% | — | |
| $30.77 | $3.03B | -5.28 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $372.25 | $10.97B | 54.42 | 33.94% | 53.92% | 19.25% | — | |
| $5.00 | $602.98M | -9.43 | -58.19% | -832.58% | -55.89% | — | |
| $5.55 | $1.36B | -21.35 | 22.09% | -13.58% | -38.11% | — |
Compare MREO vs Peers
Mereo BioPharma Group plc (MREO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MREO SEC Filings & Documents
Mereo BioPharma Group plc (MREO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when MREO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MREO Frequently Asked Questions
Mereo BioPharma Group plc (MREO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Mereo BioPharma Group plc's revenue?
Mereo BioPharma Group plc (MREO) reported $0.5M in revenue for fiscal year 2025.
Is MREO profitable?
Mereo BioPharma Group plc (MREO) reported a net loss of $35.7M for fiscal year 2025.
Dividend & Returns
What is MREO's return on equity?
Mereo BioPharma Group plc (MREO) has a return on equity (ROE) of -82.2%. Negative ROE indicates the company is unprofitable.
What is Mereo BioPharma Group plc's free cash flow?
Mereo BioPharma Group plc (MREO) had negative free cash flow of $27.0M in fiscal year 2025, likely due to heavy capital investments.